Subtotal $0.00
Shop Now
A GLP-1 pill is a tablet, swallowed once a day, that activates the same GLP-1 receptor as injectable medicines such as Ozempic and Zepbound. As of September 2026, the FDA has approved four oral GLP-1 products: Rybelsus and Ozempic tablets for type 2 diabetes, and the Wegovy pill and Foundayo for weight management. Three contain semaglutide and come with strict empty-stomach rules; Foundayo contains a different drug, orforglipron, and has no food or water restrictions. This hub compares them side by side, lists oral GLP-1 medicines still in trials, and explains why pills sold online as “GLP-1” are not the same thing.
Peptide Labs does not sell any GLP-1 medication or any prescription drug. All oral GLP-1 meds are prescription-only in the United States.
Key Takeaways
- Four oral GLP-1 products are FDA-approved: Rybelsus, Ozempic tablets, Wegovy tablets and Foundayo.
- Only the Wegovy pill and Foundayo are approved for weight management; the other two are for type 2 diabetes.
- Oral semaglutide must be taken on an empty stomach; Foundayo can be taken with or without food.
- Pfizer stopped developing its oral GLP-1 danuglipron in 2025; oral amycretin is in late-stage trials.
- Supplements and online products sold as "GLP-1 pills" contain no approved GLP-1 medicine.
What is a GLP-1 pill?
GLP-1 is a gut hormone that raises insulin when blood sugar is high, slows stomach emptying and signals fullness. Most GLP-1 medicines are peptides, which the stomach normally breaks down, so for years they were only available as injections. There are now two ways to make an oral GLP-1 work. Novo Nordisk pairs semaglutide with an absorption enhancer, which lets a small share of the swallowed dose reach the bloodstream. Eli Lilly’s orforglipron is a small molecule rather than a peptide, so it is absorbed from an ordinary tablet. Our guide to what GLP-1 is explains the hormone and lists every approved GLP-1 medicine, injections included.
Every FDA-approved GLP-1 pill in one table
The table covers every oral GLP-1 product approved in the U.S. as of September 2026. Food and water rules are summarized in general terms; the Medication Guide and pharmacist give the exact instructions. T2D means type 2 diabetes; CV means cardiovascular.
| Product | Molecule | Maker | Approved use | Approval date | Food and water rule (general) |
|---|---|---|---|---|---|
| Rybelsus | Semaglutide | Novo Nordisk | Blood sugar control in adults with T2D; CV risk reduction in high-risk T2D | September 2019 | Empty stomach in the morning, a small amount of plain water, then a wait before eating or drinking |
| Ozempic tablets | Semaglutide (newer formulation) | Novo Nordisk | Same uses as Rybelsus | Name approved February 2026; on sale May 2026 | Same empty-stomach rules as Rybelsus |
| Wegovy tablets (Wegovy pill) | Semaglutide | Novo Nordisk | Weight management in adults; CV risk reduction in adults with heart disease and excess weight | December 22, 2025 | Same empty-stomach rules |
| Foundayo | Orforglipron (small molecule) | Eli Lilly | Weight management in adults | April 1, 2026 | None; with or without food, any time of day |
Rybelsus and Ozempic tablets share one label, and the label says they cannot be swapped milligram for milligram. Our Ozempic pill guide explains the 2026 rename. The Wegovy pill and Foundayo guides cover each weight-management tablet in depth, including their trials.
Oral GLP-1 for diabetes vs weight management
The most common mix-up is assuming any oral GLP-1 is a weight-loss pill. Each product is approved only for the uses on its own label:
- Type 2 diabetes: Rybelsus and Ozempic tablets, alongside diet and exercise, to improve blood sugar control, and to lower the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes at high risk. Neither is approved for weight management.
- Weight management: the Wegovy pill and Foundayo, for adults with obesity, or with overweight and at least one weight-related condition, alongside a reduced-calorie diet and more physical activity. The Wegovy pill also carries a cardiovascular risk-reduction indication.
The trials behind the weight-management pills were separate, so their results cannot be ranked against each other. In OASIS 4, adults without diabetes on the Wegovy pill lost 13.6% of body weight on average over 64 weeks, versus 2.2% on placebo. In ATTAIN-1, adults on Foundayo lost up to 11.2% over 72 weeks, versus 2.1% on placebo. Both trials were funded by the drug makers. Lilly has also submitted orforglipron to the FDA for type 2 diabetes. There is no approved tirzepatide pill.
Why oral semaglutide has food rules and Foundayo does not
According to the Rybelsus and Ozempic tablets label, only about 0.4% to 2% of an oral semaglutide dose is absorbed, and food, other drinks and other pills taken at the same time reduce that further. That is why all three semaglutide tablets must be taken on an empty stomach with a limited amount of plain water, followed by a waiting period. Orforglipron is absorbed like most small-molecule drugs, so the Foundayo label has no food or water restrictions. The trade-off is interactions: orforglipron is broken down by the liver enzyme CYP3A4, so some common medicines change its levels, and the label advises a backup or non-oral birth control method for a period after starting and after each dose increase. A full medication list for the prescriber and pharmacist matters with any of these.
Oral GLP-1 medicines still in development
Several oral GLP-1 drugs are investigational, which means they are not approved and are available only in clinical trials. Some examples as of September 2026:
- Oral amycretin (Novo Nordisk): a single molecule that activates both the GLP-1 and amylin receptors. In June 2025 the company said it would move both the oral and injectable forms into phase 3 trials for weight management, starting in the first quarter of 2026.
- Aleniglipron (Structure Therapeutics): a small-molecule oral GLP-1 that has reported phase 2 weight-loss results, with a phase 3 program planned.
- Orforglipron for type 2 diabetes: already approved for weight management as Foundayo and under FDA review for diabetes.
Not every candidate makes it. Pfizer discontinued danuglipron, its oral GLP-1 for weight management, in April 2025. The company said liver enzyme rises across its safety database of more than 1,400 participants were in line with approved drugs in the class, but one participant had a potential drug-induced liver injury that resolved after stopping, and it ended development after reviewing the data and input from regulators.
Unapproved "GLP-1 pills" sold online and GLP-1 supplements
Search results for a GLP-1 pill also turn up products that are not FDA-approved medicines. They fall into two groups, and neither is interchangeable with the tablets in the table above:
- Unapproved drug products. Sellers offer semaglutide or tirzepatide as drops, sublingual tablets, lozenges or capsules, sometimes labeled “for research use only”. In January 2025, South Carolina’s attorney general warned that such forms have never been evaluated by any regulator. The FDA says unapproved and compounded GLP-1 products are not reviewed for safety, effectiveness or quality, that counterfeits exist, and it sent warning letters to five online sellers in August 2026. Our guide to compounded semaglutide and tirzepatide explains the rules.
- Dietary supplements. Capsules and gummies marketed for “GLP-1 support” usually contain fiber, probiotics or berberine. They contain no GLP-1 receptor agonist and cannot legally claim to work like a prescription drug. See what GLP-1 support supplements are and our look at “nature’s Ozempic” claims.
The FDA’s advice is to get GLP-1 meds only with a prescription from a licensed prescriber, filled at a state-licensed pharmacy.
Side effects shared by oral GLP-1 meds
Because they act on the same receptor, the oral GLP-1 tablets share most of their safety information with the injections. The most common side effects are digestive, such as nausea, diarrhea, vomiting and constipation, mostly while the dose is being raised. All four labels carry a boxed warning about thyroid C-cell tumors seen in rodents and list warnings about pancreatitis, gallbladder problems, kidney injury from dehydration and low blood sugar when combined with insulin or a sulfonylurea. Our semaglutide side effects guide goes through the semaglutide labels.
Frequently Asked Questions
Is there an FDA-approved GLP-1 pill for weight loss?
Yes. The Wegovy pill (oral semaglutide, approved December 2025) and Foundayo (orforglipron, approved April 2026) are approved for weight management in adults with obesity, or overweight with a weight-related condition.
What is the difference between Rybelsus and the Wegovy pill?
Both contain semaglutide, but Rybelsus is approved for type 2 diabetes and the Wegovy pill for weight management and heart risk reduction. They come in different strengths and are not interchangeable.
Which oral GLP-1 can be taken with food?
Foundayo. Its label has no food or water restrictions. The semaglutide tablets must be taken on an empty stomach with a small amount of plain water.
Is oral GLP-1 as effective as the injection?
The pills and injections were tested in different trials, so there is no simple answer. A prescriber weighs trial results, other conditions, side effects, cost and whether a pill or weekly injection suits the person.
Are GLP-1 pills sold without a prescription real?
No approved GLP-1 medicine is sold over the counter. Products sold without a prescription are either supplements with no GLP-1 drug or unapproved products the FDA warns about.
What happened to danuglipron?
Pfizer stopped developing it in April 2025 after a potential case of drug-induced liver injury in one trial participant, which resolved when the drug was stopped.
This article is general information, not medical advice. Peptide Labs does not sell prescription drugs, including any medicine named here. Ask a pharmacist or prescriber how this information applies to you.
Last reviewed September 2026.
Related guides: GLP-1 Patches: What They Contain and Do They Work?, Microdosing GLP-1: What It Is, the Evidence and the Risks, What Is GLP-1? The Hormone, How GLP-1 Drugs Work and Every FDA-Approved Option.